Equities analysts expect NeoGenomics, Inc. (NASDAQ:NEO) to post $65.83 million in sales for the current quarter, Zacks reports. Four analysts have made estimates for NeoGenomics’ earnings. The highest sales estimate is $69.80 million and the lowest is $61.19 million. NeoGenomics reported sales of $60.49 million during the same quarter last year, which indicates a positive year over year growth rate of 8.8%. The firm is expected to report its next earnings report before the market opens on Wednesday, February 21st.
On average, analysts expect that NeoGenomics will report full-year sales of $65.83 million for the current financial year, with estimates ranging from $238.98 million to $264.03 million. For the next year, analysts anticipate that the company will post sales of $278.03 million per share, with estimates ranging from $264.03 million to $292.93 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow NeoGenomics.
NEO has been the topic of several research reports. BidaskClub downgraded NeoGenomics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 18th. Janney Montgomery Scott reaffirmed a “buy” rating on shares of NeoGenomics in a report on Thursday, October 26th. Zacks Investment Research raised NeoGenomics from a “sell” rating to a “hold” rating in a report on Thursday, October 26th. CIBC set a $19.00 price target on NeoGenomics and gave the company a “neutral” rating in a research note on Wednesday, January 3rd. Finally, Royal Bank of Canada set a $23.00 price target on NeoGenomics and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $15.83.
NeoGenomics (NASDAQ:NEO) opened at $7.72 on Thursday. NeoGenomics has a 1-year low of $7.12 and a 1-year high of $11.63. The company has a current ratio of 2.14, a quick ratio of 1.99 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $620.76, a price-to-earnings ratio of -22.06, a price-to-earnings-growth ratio of 3.16 and a beta of 0.84.
Hedge funds have recently bought and sold shares of the company. Empirical Finance LLC acquired a new position in shares of NeoGenomics in the 3rd quarter valued at $159,000. Campbell & CO Investment Adviser LLC lifted its stake in shares of NeoGenomics by 64.0% in the 3rd quarter. Campbell & CO Investment Adviser LLC now owns 21,544 shares of the medical research company’s stock valued at $240,000 after purchasing an additional 8,404 shares during the period. OLD National Bancorp IN lifted its stake in shares of NeoGenomics by 38.2% in the 3rd quarter. OLD National Bancorp IN now owns 21,714 shares of the medical research company’s stock valued at $242,000 after purchasing an additional 6,004 shares during the period. FDx Advisors Inc. lifted its stake in shares of NeoGenomics by 37.7% in the 3rd quarter. FDx Advisors Inc. now owns 23,029 shares of the medical research company’s stock valued at $256,000 after purchasing an additional 6,306 shares during the period. Finally, Voya Investment Management LLC lifted its stake in shares of NeoGenomics by 15.4% in the 2nd quarter. Voya Investment Management LLC now owns 29,333 shares of the medical research company’s stock valued at $263,000 after purchasing an additional 3,921 shares during the period. 83.37% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Zacks: Analysts Expect NeoGenomics, Inc. (NEO) Will Announce Quarterly Sales of $65.83 Million” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/01/zacks-analysts-expect-neogenomics-inc-neo-will-announce-quarterly-sales-of-65-83-million.html.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Get a free copy of the Zacks research report on NeoGenomics (NEO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.